Evidence map›Paper›PMID 38331952›Full record

Articlenpj aging2024

Cost of care for Alzheimer's disease and related dementias in the United States: 2016 to 2060.

Arindam Nandi, Nathaniel Counts, Janina Bröker, Sabrina Malik, Simiao Chen, Rachael Han, Jessica Klusty, Benjamin Seligman, Daniel Tortorice, Daniel Vigo and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in npj aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 3 pooled it
147.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 3 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Cost-effectiveness of testing biofluid biomarkers to diagnose Alzheimer's disease: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Pooled it
  2. Diagnostic performance of salivary markers of Alzheimer's disease: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. The cost of dementia in the United States in 2026.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  18. Article
  19. A dynamic microsimulation method for estimating dementia costs in the United States.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 4 countries.

Arindam NandiThe Population Council, 1 Dag Hammarskjold Plaza, New York, NY, 10017, USA. anandi@popcouncil.org.ORCID http://orcid.org/0000-0002-3967-2424
Nathaniel CountsOffice of the Commissioner of Health & Mental Hygiene for the City of New York, New York, NY, USA.
Janina BrökerThe Brookings Institution, Washington, DC, USA.
Sabrina MalikData for Decisions, LLC, Waltham, MA, USA.
Simiao ChenUniversity of Heidelberg, Heidelberg, Germany.
Rachael HanDepartment of Molecular and Cellular Biology and The Center for Brain Science, Harvard University, Cambridge, MA, USA.
Jessica KlustyData for Decisions, LLC, Waltham, MA, USA.
Benjamin SeligmanDivision of Geriatric Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Daniel TortoriceCollege of the Holy Cross, Worcester, MA, USA.
Daniel VigoUniversity of British Columbia, Vancouver, BC, V6T 1Z4, Canada.
David E BloomHarvard T.H. Chan School of Public Health, Boston, MA, USA.
Harvard University · USHealth Decisions (United States) · USBrookings Institution · USCollege of the Holy Cross · USHeidelberg University · DENew York City Department of Health and Mental Hygiene · USRegione Siciliana · ITUniversity of British Columbia · CAUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medical and long-term care for Alzheimer's disease and related dementias (ADRDs) can impose a large economic burden on individuals and societies. We estimated the per capita cost of ADRDs care in the in the United States in 2016 and projected future aggregate care costs during 2020-2060. Based on a previously published methodology, we used U.S. Health and Retirement Survey (2010-2016) longitudinal data to estimate formal and informal care costs. In 2016, the estimated per patient cost of formal care was $28,078 (95% confidence interval [CI]: $25,893-$30,433), and informal care cost valued in terms of replacement cost and forgone wages was $36,667 ($34,025-$39,473) and $15,792 ($12,980-$18,713), respectively. Aggregate formal care cost and formal plus informal care cost using replacement cost and forgone wage methods were $196 billion (95% uncertainty range [UR]: $179-$213 billion), $450 billion ($424-$478 billion), and $305 billion ($278-$333 billion), respectively, in 2020. These were projected to increase to $1.4 trillion ($837 billion-$2.2 trillion), $3.3 trillion ($1.9-$5.1 trillion), and $2.2 trillion ($1.3-$3.5 trillion), respectively, in 2060.

Identifiers

PMID38331952
PMCPMC10853249
OpenAlexW4391645822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.